PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Company Details
- Employees
- 72
- Founded
- -
- Address
- 60 Avenue Rockefeller, Bâtiment Bioserra,france
- Industry
- Biotechnology
- Website
- erytech.com
- Keywords
- Biotechnology, phage, innovation, bacterial infection, viruses, staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, phxm.
- HQ
- LYON, Rhône-Alpes
Phaxiam Therapeutics Questions
Phaxiam Therapeutics's website is erytech.com
Phaxiam Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/phaxiam
Phaxiam Therapeutics has
72 employees.
View email and phone details for 72
employees at Phaxiam Therapeutics.
Phaxiam Therapeutics's industry is
Biotechnology
Phaxiam Therapeutics's top competitors are
Bioaster,
Adocia,
Innate Pharma,
Cellectis,
Abivax,
Maat Pharma,
Valneva,
Enyo Pharma,
Transgene,
Ose Immunotherapeutics.
Phaxiam Therapeutics's categories are Biotechnology
Phaxiam Therapeutics's founding year is 2004
